Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: procedure (650), etiquette (1), practice (609)

VenetoclaxHigh

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (high risk) Regimen • CLL – Venetoclax (high risk) Indication • Venetoclax is indicated for the treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxHigh.pdf

Tarlatamab (EAMS)

Description: Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) Tarlatamab (EAMS) Regimen • SCLC – Tarlatamab (EAMS) Indication • Tarlatamab is indicated as monotherapy for the
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Tarlatamab-EAMS-Ver-1.0.pdf

Alemtuzumab

Description: Chemotherapy Protocol TPLL Regimen Alemtuzumab • TPLL – Alemtuzumab Indication • The treatment of adult patients with TPLL in the first line setting. In
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/TPLL/Alemtuzumab-Ver1.pdf

Carboplatin and Vinorelbine (intravenous)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN-VINORELBINE (Intravenous) Regimen • NSCLC – Carboplatin-Vinorelbine (intravenous) Indication • First line therapy of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CarboplatinandVinorelbineintravenous.pdf

Cytarabine1500

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA CYTARABINE (1500mg/m2) In-Patient Regimen Regimen • Acute Myeloid Leukaemia – InP-Cytarabine (1500mg/m2) Indica
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Cytarabine1500.pdf

Crizotinib Ver 1

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CRIZOTINIB This protocol may require funding Regimen NSCLC - Crizotinib Indication The treatment of
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/CrizotinibVer1.pdf

Fluorouracil Mitomycin RT

Description: Chemotherapy Protocol BLADDER CANCER FLUOROURACIL-MITOMYCIN-RADIOTHERAPY Regimen • Bladder Cancer – Fluorouracil-Mitomycin-Radiotherapy Indication • Muscle invasive bladder cancer • WHO performance status
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Fluorouracil-Mitomycin-RT.pdf

Everolimus v1.1

Description: Chemotherapy Protocol RENAL CELL EVEROLIMUS This protocol may require funding Regimen Renal Cell - Everolimus Indication Advanced renal cell carcinoma that has
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Everolimus-v1.1.pdf

Obinutuzumab_maintenance

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Obinutuzumab (Maintenance) Regimen • NHL – Obinutuzumab (Maintenance) Indication • Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Obinutuzumab-maintenance.pdf

InP methotrexate

Description: Chemotherapy Protocol LYMPHOMA METHOTREXATE Inpatient Regimen Regimen • Lymphoma – InP-Methotrexate Indication • Non-Hodgkin’s Lymphoma (NHL), in particular treatment of primary
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-methotrexate.pdf

101 to 110 of 698

Previous … 9 10 11 12 13 … Next